Early Data Suggest Novo Nordisk's Long-Acting Insulin Degludec On Par With Sanofi's Lantus
This article was originally published in The Pink Sheet Daily
Executive Summary
Much anticipated Phase II data suggest Degludec is as good as Lantus, but unseating the market leader will require showing superiority in either maintaining blood glucose control or incidence of hypoglycemia.